{"id":"W2947202175","doi":"10.1200/jco.2019.37.15_suppl.9514","title":"Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Ipilimumab; Discontinuation; Metastatic melanoma; Internal medicine; Melanoma; Tolerability; Toxicity; Oncology; Surgery; Cancer; Adverse effect; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005224161,0.000933714,0.001457333,0.0004969725,0.0003923409,0.001175049,0.001398142,0.0009339961,0.004098638],"category_scores_gemma":[0.003256748,0.0004830961,0.002228927,0.0009716724,0.0004328433,0.0007266084,0.0007631661,0.00225244,0.001014455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001970287,"about_ca_system_score_gemma":0.002535754,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002791805,"about_ca_topic_score_gemma":0.006902959,"domain_scores_codex":[0.9982274,0.0007460405,0.0001310547,0.0003862201,0.0002996274,0.0002096424],"domain_scores_gemma":[0.9971707,0.0005596581,0.000688777,0.0004802019,0.0003488447,0.0007518382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6602832,0.02784122,0.1574333,0.003054057,0.01409701,0.0006089766,0.0004042482,0.003848974,0.02284723,0.0004956971,0.02217223,0.08691384],"study_design_scores_gemma":[0.2571868,0.2752648,0.3978038,0.0006390916,0.01278352,0.002010372,0.0003692406,0.003293789,0.008441277,0.0005903316,0.04142196,0.0001951024],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655781,0.006446721,0.0008602927,0.000443345,0.0001040842,0.003093939,0.02117312,0.0000560095,0.002244314],"genre_scores_gemma":[0.9479685,0.002730391,0.001778221,0.001184483,0.0001540529,0.002063082,0.04177159,0.00005014745,0.002299534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005224161,"threshold_uncertainty_score":0.0276283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05677921057621099,"score_gpt":0.4489293667916658,"score_spread":0.3921501562154548,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}